Methods and compositions for preventing or treating myopia
By polarizing macrophages into M2 type in the choroid or using mast cell stabilizers or lactic acid bacteria, the problem of difficulty in inhibiting the development of myopia in the prior art is solved, and effective prevention and treatment of myopia is achieved.
Patent Information
- Application Number
- CN202380035831.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-26
- Filing Date
- 2023-04-25
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to effectively inhibit the development of myopia, especially by targeting choroid-resident immune cells to prevent or treat myopia, and the existing methods have limited effects.
The function of choroid-resident immune cells is inhibited by polarizing macrophages in the choroid into M2 macrophages, or by using mast cell stabilizers or lactic acid bacteria such as Lactobacillus paracasei to regulate the function of choroid-resident immune cells.
It effectively inhibits the development of myopia, regulates the function of choroid-resident immune cells, prevents the elongation of the axial length and the decrease in diopter, maintains the thickness of the choroid, and thus prevents or treats myopia.
Smart Images

Figure CN119072322A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a method and composition for preventing or treating myopia, and specifically to a composition acting on immune cells in the choroid to inhibit the development of myopia, and specifically to a method and composition acting by inducing polarization into M2 macrophages, or by regulating the function of choroid-resident immune cells, such as administering mast cell stabilizers, chemical mediator release inhibitors, or lactic acid bacteria. Background Art
[0002] Myopia is a condition in which the focus is focused in front of the retina due to the elongation of the axial length of the eye. It can be said that the longer the axial length, the higher the degree of myopia. With the increase in the prevalence of myopia, people are paying more and more attention to the factors related to the onset of myopia and methods to inhibit or prevent the development of myopia. Studies in recent years have shown that the choroid plays an important role in regulating eye growth and the development of myopia, and choroidal thinning is a structural feature of myopia. There is a negative correlation between choroidal thickness and axial length, which suggests that changes in choroidal thickness may be a predictive biomarker for axial length elongation. However, the detailed mechanism of the choroid's involvement in the onset and development of myopia is still unclear.
[0003] The choroid is a tissue covering the outer side of the retina with abundant tiny blood vessels. In addition to providing oxygen and nutrients to retinal cells, it also has the function of providing growth factors, which are involved in the tissue remodeling of the sclera on the outer side of the eyeball and the regulation of eye growth. Choroidal thickness reduction or reduced blood flow may lead to symptoms of scleral ischemia and hypoxia, thereby affecting changes in the scleral structure that elongate the axial length of the eye. Therefore, maintaining and increasing the thickness and blood flow of the choroid has attracted attention as a new target for the prevention and treatment of myopia.
[0004] A method for suppressing the progression of myopia by maintaining and increasing the thickness of the choroid has been proposed, for example, the intake of crocetin (see Non-Patent Document 1), ultraviolet irradiation (Non-Patent Document 2), etc. have been proposed.
[0005] It is known that crocetin has anti-inflammatory and immunomodulatory effects, and it is known that these effects are expressed by regulating the Th1 / Th2 and Th17 / Treg balance of T cells and inhibiting the NF-κB pathway of cells such as macrophages that produce inflammatory mediators (TNF-α, IL-6, IFN-γ, etc.) (Non-patent Documents 3 to 5).
[0006] There are 13 types of cells in the choroid, 4 of which are immune cells. Tissue-resident immune cells are responsible for maintaining tissue homeostasis and structure in addition to immune responses. For example, it has been reported that the choroid becomes thinner in macrophage-deficient mice and mice in which mast cell degranulation is induced (Non-Patent Documents 6-7).
[0007] Prior art literature
[0008] Non-patent literature
[0009] Non-patent literature 1: Mori et al., Sci Rep. 2019.22;9(1):295.
[0010] Non-patent literature 2: Jiang et al. Proc Natl Acad Sci USA. 2021.1; 118(22): e2018840118.
[0011] Non-patent literature 3: Oxid Med Cell Longev. 2021Sep 10; 2021: 6631929.
[0012] Non-patent document 4: Eur J Pharmacol. 2012 Jan 15; 674(2-3): 391-6.
[0013] Non-patent literature 5: Biofactors. 2023 Feb 6. doi: 10.1002 / biof.1942.
[0014] Non-patent literature 6: Elife. 2020Apr 1; 9: e55564.
[0015] Non-patent literature 7: FASEB J. 2020Aug; 34(8): 10117-10131. Summary of the invention
[0016] Problem that the invention aims to solve
[0017] The present disclosure aims to provide a method for preventing or treating myopia and a composition used therefor, especially a composition targeting choroidal resident immune cells, especially targeting macrophages and mast cells.
[0018] Solutions for solving problems
[0019] The inventors have found that polarizing macrophages in the choroid into M2 macrophages can inhibit choroidal thinning, thereby effectively preventing and treating myopia.
[0020] In addition, mast cells are mostly distributed around small blood vessels, and are also found in the choroid, a tissue composed of blood vessels, indicating that they are involved in maintaining the morphology of the choroid. Therefore, the inventors found that the development of myopia can be inhibited by dropping a drug (mast cell stabilizer) that inhibits mast cell degranulation into the eye. That is, the inventors found that the development of myopia can be inhibited by dropping a mast cell stabilizer (sodium cromoglycate, potassium pemirolast) as a kind of antiallergic drug on model mice with myopia caused by wearing negative lenses. It should be noted that even if other antiallergic drugs, i.e., antihistamines (levocabastine) are dropped on mice induced to myopia by wearing negative lenses, the development of myopia cannot be inhibited.
[0021] In addition, it is known that lactobacillus such as Lactobacillus paracasei can induce and activate polarization to M2 macrophages by administration, and the inventor has found that the use of lactobacillus such as Lactobacillus paracasei can inhibit the development of myopia. These findings are combined with the research results in the above-mentioned non-patent literature 6 to 7, showing that if the choroid structure (thickness) can be maintained by intervention with immune cells resident in the choroid as a target, the development of myopia may be inhibited, and these research results believe that the immune cells present in the choroid such as macrophages and mast cells are targeted, and the composition induced to the appropriate state by their respective characteristics has an inhibitory effect on the development of myopia. The present invention is based on these research results and includes the following aspects.
[0022] [Aspect 1]
[0023] A method for inhibiting, improving or treating myopia comprises administering a therapeutically effective amount of a choroid-resident immune cell function regulator or lactic acid bacteria to a subject in need of treatment.
[0024] [Aspect 2]
[0025] The method according to aspect 1, wherein the choroid-resident immune cell function regulator is an M2 macrophage polarization inducer, a mast cell stabilizer, or a chemical mediator release inhibitor.
[0026] [Aspect 3]
[0027] The method according to aspect 2, wherein the M2 macrophage polarization inducer is selected from the group consisting of proteins, peptides, nucleic acids, low molecular weight compounds, and high molecular weight compounds.
[0028] [Aspect 4]
[0029] The method according to aspect 2, wherein the M2 macrophage polarization inducer is selected from the group consisting of IL-4, IL-10, IL-13, TLR2, 4, 7, 9 and their ligands, bisantrene dihydrochloride, triptolide, lovastatin, QS11, regorafenib, sorafenib, ixazomib, GW-843682X, KW 2449, axitinib, JTE 013, purmorphamine, arcyriaflavin A, dasatinib, NVP-LDE225, 1-naphthyl PP1, MGCD-265, and bosutinib.
[0030] [Aspect 5]
[0031] A method according to aspect 2, wherein the mast cell stabilizer or chemical mediator release inhibitor is cromolyn, or pemirolast or a salt thereof.
[0032] [Aspect 6]
[0033] The method according to aspect 1, wherein the lactic acid bacteria are of the genus Lactobacillus.
[0034] [Aspect 7]
[0035] The method according to aspect 1, wherein the lactic acid bacteria is Lactobacillus paracasei.
[0036] [Aspect 8]
[0037] The method according to aspect 1, wherein the choroidal resident immune cell function regulator or lactic acid bacteria is contained in a pharmaceutical composition, a supplement or a food.
[0038] [Aspect 9]
[0039] A method according to aspect 1, wherein reduction in refractive power, axial elongation, and / or choroidal thinning can be suppressed.
[0040] [Aspect 10]
[0041] A composition for inhibiting or treating myopia, comprising a therapeutically effective amount of a choroidal resident immune cell function regulator or lactic acid bacteria.
[0042] [Aspect 11]
[0043] A supplement for inhibiting or improving myopia, comprising an effective amount of a choroid-resident immune cell function regulator or lactic acid bacteria.
[0044] [Aspect 12]
[0045] A food for inhibiting or improving myopia, comprising an effective amount of a choroidal resident immune cell function regulator or lactic acid bacteria.
[0046] [Aspect 13]
[0047] Use of a choroidal resident immune cell function regulator or lactic acid bacteria in the manufacture of a medicament for inhibiting or treating myopia.
[0048] [Aspect 14]
[0049] Use of a choroid-resident immune cell function regulator or lactic acid bacteria for inhibiting or treating myopia.
[0050] Effects of the Invention
[0051] According to the present disclosure, a new method for preventing and treating myopia can be provided by regulating the function of choroid-resident immune cells, more specifically, by inducing polarization into M2 macrophages in the choroid, or by administering mast cell stabilizers, chemical mediator release inhibitors, or lactic acid bacteria. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 The results of myopia induction by LPS administration; (A) is a diagram showing the experimental schedule; (B) is a graph showing changes in refractive power (left), axial length (center), and choroidal thickness (right).
[0053] Figure 2 The graphs show the changes in the expression of M1 macrophage marker genes and oxidative stress-related genes caused by the administration of LPS.
[0054] Figure 3 The results of M2 macrophage polarization induction caused by the administration of IL-4; wherein (A) is a diagram showing the experimental schedule; (B) is a graph showing the changes in the expression of CD206 protein and phosphorylated STAT6 in the choroid caused by the administration of IL-4; (C) is a graph showing the changes in the expression of CD163 and CD206 mRNA caused by the administration of IL-4.
[0055] Figure 4 The graphs show changes in the expression of M2 macrophage marker genes and oxidative stress-related genes caused by the administration of IL-4.
[0056] Figure 5The figures are the results of an experiment on inhibition of myopia caused by administration of IL-4; wherein (A) is a diagram showing the experimental schedule; and (B) is a diagram showing changes in refraction (left), axial length (center), and choroidal thickness (right) caused by administration of IL-4 during myopia induction.
[0057] Figure 6 The figures are the results of myopia inhibition and M2 macrophage polarization induction caused by the administration of IL-13; wherein, (A) is a diagram showing the experimental schedule; (B) is a graph showing the changes in refraction (upper left), axial length (upper right), choroidal thickness (lower left), and blood flow (lower right) caused by the administration of IL-13 during myopia induction; (C) is a graph showing the changes in the number of macrophages and the proportion of M2 macrophages caused by myopia induction and the administration of IL-13.
[0058] Figure 7 The results show the effect of intraocular instillation of mast cell stabilizers on inhibiting myopia; wherein, (A) is a graph showing the change in axial length; (B) is a graph showing the change in refractive power; (C) is a graph showing the change in choroidal thickness; the left and right sides respectively show the control group vs the intraocular instillation of pyraclostrobin potassium group, and the control group vs the intraocular instillation of cromolyn; *p<0.05, **p<0.01, ***p<0.001, student's t-test.
[0059] Figure 8 The graphs are comparative graphs showing the effects of ocular instillation of mast cell stabilizers and histamine receptor blockers on inhibiting myopia; wherein, (A) is a graph showing the change in axial length; (B) is a graph showing the change in refractive power; (C) is a graph showing the change in choroidal thickness; from left to right, the control group, the ocular instillation of levocabastine group (histamine receptor blocker), and the ocular instillation of pemirolast potassium group (mast cell stabilizer) are shown respectively; *p<0.05, **p<0.01, ***p<0.001, student's t-test.
[0060] Fig. 9 The figures show the effect of administering Lactobacillus paracasei on inhibiting the progression of myopia; wherein (A) is a graph showing the change in axial length; (B) is a graph showing the change in refractive power; (C) is a graph showing the change in choroidal thickness; the left and right sides respectively show a control group and a group administered with Lactobacillus paracasei. DETAILED DESCRIPTION
[0061] The present invention will be described in detail below. The present invention is not limited to the following embodiments and examples, and includes various modifications and application examples within the scope of the gist of the present invention.
[0062] [Method for inhibiting or treating myopia]
[0063] As mentioned above, in recent years, choroidal thinning has been shown to be associated with the development of myopia. After further investigation into the factors controlling this thinning, the inventors discovered that changes in the state of macrophages in the choroid (polarization) alter choroidal thickness and control the progression of myopia.
[0064] There are two types of macrophages: M1 macrophages and M2 macrophages. M1 macrophages are mainly involved in the production of inflammation, while M2 macrophages play an antagonistic role and participate in the termination and inhibition of inflammation. The inventors first discovered that by inducing polarization toward M1 macrophages in the choroid, choroid thinning and myopia aggravation can be observed. On the other hand, by inducing polarization toward M2 macrophages, choroid thinning and myopia aggravation can be inhibited. In addition, mast cells are mostly distributed around small blood vessels, and they are also found in the choroid, a tissue composed of blood vessels, indicating that they are involved in maintaining the morphology of the choroid. The inventors found that by instilling into the eye an agent that inhibits mast cell degranulation (mast cell stabilizer), the development of myopia can be inhibited. Moreover, it is known that lactic acid bacteria such as Lactobacillus paracasei induce and activate polarization to M2 macrophages by administration, and the inventors have found that the use of lactic acid bacteria such as Lactobacillus paracasei inhibits myopia development. Thus, the inventors have found that myopia development can be inhibited by regulating the function of choroidal resident immune cells.
[0065] Therefore, one aspect of the present disclosure relates to a method for inhibiting, improving or treating myopia by regulating the function of choroid-resident immune cells, more specifically, by polarizing macrophages into M2 macrophages in the choroid, or by administering mast cell stabilizers, chemical mediator release inhibitors or lactic acid bacteria.
[0066] One aspect of the present disclosure relates to a method for inhibiting, improving or treating myopia by regulating the function of choroid-resident immune cells, more specifically, by inducing polarization of M2 macrophages in the choroid using an M2 macrophage polarization inducer, or by administering a mast cell stabilizer, a chemical mediator release inhibitor or lactic acid bacteria.
[0067] One aspect of the present disclosure relates to a method for inhibiting reduced refractive power, axial elongation and / or choroidal thinning, comprising: in a subject in need of treatment, regulating the function of choroid-resident immune cells, more specifically, delivering an M2 macrophage polarization inducer to the subject's choroid, or administering a mast cell stabilizer, a chemical mediator release inhibitor, or lactic acid bacteria.
[0068] In addition, one aspect of the present invention also relates to a screening method for finding substances that regulate the function of choroidal resident immune cells, such as components that promote polarization into M2 macrophages, which are used to control choroidal thinning as a pathogenesis of myopia, and a screening method for finding effective ingredients for preventing and treating myopia.
[0069] <Choroid-resident immune cell function regulator>
[0070] Choroidal resident immune cell function regulators are substances that regulate the function of choroidal resident immune cells. As substances that regulate the function of choroidal resident immune cells, substances that regulate to suppress inflammation in the choroid and substances that regulate to make the choroid an anti-inflammatory environment are preferred. Choroidal resident immune cells include macrophages, mast cells, etc. Choroidal resident immune cell function regulators include M2 macrophage polarization inducers, mast cell stabilizers, chemical mediator release inhibitors, lactic acid bacteria, etc.
[0071] <M2 macrophage polarization inducer>
[0072] Macrophages are divided into inflammatory M1 macrophages and anti-inflammatory M2 macrophages with different functions. They polarize in response to signals from cytokines and irritating components and express specific functions.
[0073] Therefore, the M2 macrophage polarization inducer disclosed in the present invention includes various substances involved in signal transduction for inducing M2 macrophage polarization in the choroid, and proteins, peptides, nucleic acid drugs, low molecular weight compounds, high molecular weight compounds, etc. can be used without particular limitation.
[0074] For example, in addition to IL-4, IL-13 and other cytokines produced by Th2 cells, there are also leucine zipper transcription factor c-Maf, carbohydrate binding lectin galectin-3, etc. In addition, it is known that there are multiple populations of M2 macrophages. In addition to the aforementioned IL-4 and IL-13 that induce M2a macrophages, IL-10 and glucocorticoids (GC) involved in the induction of M2c macrophages, TLR2, TLR4, TLR7, TLR9 and their ligands (ligands for TLR) involved in the induction of M2d macrophages, etc. can also be listed as M2 macrophage polarization inducers in the present disclosure.
[0075] In addition, in the examples of the M2 macrophage polarization inducer in the present disclosure, various low molecular weight compounds include: bisantrene dihydrochloride, triptolide, lovastatin, QS11, regorafenib, sorafenib, ixazomib, GW-843682X, KW 2449, axitinib, JTE 013, purmorphamine, arcyriaflavin A, dasatinib, NVP-LDE225, 1-naphthyl PP1, MGCD-265, bosutinib, etc.
[0076] Agonists of the above substances can also be used as M2 macrophage polarization inducers. It should be noted that, for example, those skilled in the art can evaluate whether a substance has the ability to induce M2 macrophage polarization by culturing mononuclear cell lines such as RAW264 cells, J774 cells, and U937 cells, mouse peritoneal macrophages, and bone marrow-derived macrophages in a culture medium containing an evaluation object substance, and using an in vitro evaluation system for evaluating the expression of M2 macrophage markers, thereby obtaining M2 macrophage polarization inducers suitable for use in the methods and compositions disclosed herein in addition to the M2 macrophage polarization inducers specifically described herein.
[0077] If the M2 macrophage polarization inducer is a protein or peptide, it can be administered to the subject in the form of DNA or RNA encoding them. The nucleic acid encoding the M2 macrophage polarization inducer can be administered to the subject using a plasmid or an expression vector. The expression vector can be, for example, a viral vector, particularly an adenovirus vector, but is not limited thereto. Other available viral vectors include, for example, retrovirus, adeno-associated virus, pox, baculovirus, vaccinia, herpes simplex, Epstein-Barr virus, geminivirus, and cauliflower mosaic virus vectors. The nucleic acid encoding the M2 macrophage polarization inducer may include a regulatory element for choroidal or RPE-specific expression of a protein. In other words, the nucleic acid encoding the M2 macrophage polarization inducer can be operably connected to a regulatory element such as a promoter or enhancer.
[0078] <Mast cell stabilizers>
[0079] Mast cell stabilizer is also called mast cell stabilizer or mast cell stabilizer. For example, mast cell stabilizer is a drug that inhibits mast cell release of allergic substances, for example, a drug that stabilizes the cell membrane of mast cells to inhibit mast cell release of allergic substances. Mast cell stabilizers include, for example, azalast hydrate solution (pentenesone), amlexanox (elixir), pemilast potassium (Yan Lishuang), pemilast potassium (Pemilaston), sodium cromoglycate (Yan Tai), tranilast (Lichuanbei), tranilast (Tramelas), ibulast (Ketaisi), β2-adrenergic agonist, sodium cromoglycate, cromoglycate, ketotifen, methylxanthine, omalizumab, pemilast, quercetin, etc., preferably cromoglycate, or pemilast or its salt, etc.
[0080] <Chemical mediator release inhibitors>
[0081] Chemical mediator release inhibitors are, for example, drugs that inhibit allergic reactions by inhibiting the release of chemical mediators by immune cells such as mast cells, for example, drugs that stabilize the cell membrane of mast cells (mast cells) to prevent the release of histamine, etc., for example, drugs that inhibit mast cells from releasing allergic substances (substances that cause allergic reactions) such as histamine, LTB4, LTC4, LTD4, PGD2, TXB2, and PAF. Chemical mediator release inhibitors include, for example, azalast hydrate solution (pentenesone), amlexanox (elixir), pemilast potassium (Yan Lishuang), pemilast potassium (Pemilaston), sodium cromoglycate (Yan Tai), tranilast (Lichuanbei), tranilast (Tramelas), ibulast (Ketaisi), β2-adrenergic agonists, sodium cromoglycate, cromoglycate, ketotifen, methylxanthine, omalizumab, pemilast, quercetin, etc., preferably cromoglycate, or pemilast or its salt, etc.
[0082] <Lactic acid bacteria>
[0083] Examples of lactic acid bacteria include homotypic lactic acid bacteria and heterotypic lactic acid bacteria. In addition, examples of lactic acid bacteria include spherical lactic acid cocci and rod-shaped lactobacilli. Examples of lactic acid bacteria include Gram-positive, bacilli or cocci, spore-free, inactive, lactic acid produced that accounts for more than 50% of glucose consumption, and must require nicotinic acid (B3). Examples of lactic acid bacteria include intestinal lactic acid bacteria, animal lactic acid bacteria, plant lactic acid bacteria, marine lactic acid bacteria, etc. Examples of lactic acid bacteria include lactobacillus lactic acid bacteria and actinomycetes lactic acid bacteria. Examples of lactobacillus lactic acid bacteria include lactobacillus lactic acid bacteria, enterococcus lactic acid bacteria, lactococcus lactic acid bacteria, pediococcus lactic acid bacteria, Leuconostoc lactic acid bacteria, and Streptococcus lactic acid bacteria. Examples of lactic acid bacteria belonging to the phylum Actinomycetes include lactic acid bacteria belonging to the genus Bifidobacterium. Examples of lactic acid bacteria of the genus Lactobacillus include Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus brevis, Lactobacillus delbrueckii, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus bulgaricus, Lactobacillus gasseri, Lactobacillus acidophilus, Lactobacillus fructivorans, Lactobacillus hilgardii, Lactobacillus rhamnosus, Lactobacillus plantarum, and Lactobacillus casei Shirota. Examples of lactic acid bacteria belonging to the genus Enterococcus include Enterococcus faecalis and Enterococcus faecium. Examples of lactic acid bacteria belonging to the genus Lactococcus include Lactococcus lactis and Lactococcus cremoris. Examples of lactic acid bacteria belonging to the genus Pediococcus include Pediococcus damnosus.Examples of lactic acid bacteria of the genus Leuconostoc include Leuconostoc mesenteroides, etc. Examples of lactic acid bacteria of the genus Streptococcus include Streptococcus thermophiles and Streptococcus mutans, etc. Examples of lactic acid bacteria of the genus Bifidobacterium include Bifidobacterium bifidum and Bifidobacterium adolescentis, etc.
[0084] It is known that the symptoms of non-alcoholic fatty liver disease can be improved by converting Kupffer cells (liver resident macrophages) of the liver into M2 by administering Lactobacillus paracasei (Sohn et al, Dig Dis Sci, 2015 Nov; 60(11): 3340-50). It is known that the administration of Lactobacillus paracasei can alleviate retinal degeneration caused by blue light by activating M2 macrophages (Morita et al, Nutrients, 2018 Dec 15; 10(12): 1991). It is known that the administration of Lactobacillus plantarum can alleviate colitis by promoting the polarization of M1 macrophages to M2 macrophages (Jang et al, Int Immunopharmacol, 2014 Jul; 21(1): 186-92). It is known that administration of Lactobacillus brevis relieves colitis by promoting polarization of M1 macrophages to M2 macrophages (Jang et al, J Appl Microbiol, 2013 Sep; 115 (3): 888-96). Thus, it is known that lactic acid bacteria of the genus Lactobacillus and the order Lactobacillus induce and activate polarization to M2 macrophages by administration. Therefore, the lactic acid bacteria are preferably lactic acid bacteria of the genus Lactobacillus and the order Lactobacillus.
[0085] DDS can be used to deliver choroid-resident immune cell function modulators such as M2 macrophage polarization inducers, mast cell stabilizers, and chemical mediator release inhibitors to the choroid of a subject.
[0086] For example, if the choroid-resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, and chemical mediator release inhibitors are nucleic acids, then the DNA or RNA (messenger RNA) encoding the choroid-resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, and chemical mediator release inhibitors can be administered to the subject using DDS such as liposomes. Other available DDSs include charged lipids, nucleic acid-protein complexes, and biopolymers. In addition, the choroid-resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, and chemical mediator release inhibitors can also be administered to the subject in the form of proteins. Administration can be performed, for example, by local administration to the choroid.
[0087] Delivery of choroidal resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, and chemical mediator release inhibitors to the choroid of the object can be carried out by transplanting cells that secrete choroidal resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, and chemical mediators to the object. Cells that secrete choroidal resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, and chemical mediators can be, for example, retinal pigment epithelial cells (RPE) or the like. Alternatively, it can also be a genetically engineered cell to secrete choroidal resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, and chemical mediators.
[0088] The subject of the method for inhibiting or treating myopia of the present disclosure may be a mammal including a human, a non-human mammal including a dog, a cat, a cow and a horse, preferably a human.
[0089] [Composition for inhibiting or treating myopia]
[0090] One aspect of the present disclosure relates to a composition for inhibiting, improving or treating myopia using choroidal resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, chemical mediator release inhibitors or lactic acid bacteria. More specifically, one aspect of the present disclosure relates to a composition for inhibiting or treating myopia, which contains a therapeutically effective amount of choroidal resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, chemical mediator release inhibitors or lactic acid bacteria. Such a composition can be used to deliver choroidal resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, chemical mediator release inhibitors or lactic acid bacteria to the choroid of a subject. Such a composition can be a pharmaceutical composition, a food, or a supplement.
[0091] The pharmaceutical composition of the present disclosure is administered topically to the eye, for example. The administration form of the composition includes, for example, eye drops (including eye ointment application, eye wash), subconjunctival administration, intraconjunctival sac administration, sub-Tenon capsule administration, and the like.
[0092] The dosage form of the present composition is not particularly limited, and may be, for example, eye drops, eye ointments, injections, patches, gels, inserts, etc., preferably eye drops. It should be noted that these dosage forms can be prepared using commonly used techniques in the field.
[0093] Eye drops can be selected and prepared from isotonic agents such as sodium chloride, potassium chloride, and concentrated glycerin; buffers such as sodium phosphate, sodium acetate, and ε-aminocaproic acid; surfactants such as polyoxyethylene sorbitan monooleate, polyoxyl (40) stearate, and polyoxyethylene solidified castor oil; stabilizers such as sodium citrate and monosodium edetate; and preservatives such as parabens, etc. as needed. The pH value can be within the acceptable range for ophthalmic preparations, and is generally preferably within the range of 4 to 8. Eye ointments can be prepared using general-purpose base materials such as white vaseline and liquid paraffin.
[0094] In addition, the pharmaceutical composition of the present disclosure is not limited to topical administration to the eye, and can also be administered by any administration route such as enteral administration (oral, via tube, injection, etc.), parenteral administration (intravenous, transarterial, transdermal, intramuscular injection, etc.). The dosage form of the composition used for these administration forms can be appropriately selected, for example, it can be a solid preparation such as tablets, granules, powders, capsules, chewables, or a liquid preparation such as a liquid, syrup, injection, infusion, etc.
[0095] The pharmaceutical composition of the present invention may be mixed with other ingredients in appropriate amounts within the scope of not impairing the effects of the present invention. Other ingredients include any carrier, buffer, diluent, excipient, suspending agent, lubricant, adjuvant, medium, delivery system, emulsifier, tablet decomposing material, absorbent, preservative, surfactant, colorant, flavor or sweetener, etc. These ingredients can be prepared alone or in appropriate combination of two or more.
[0096] The content ratio of the M2 macrophage polarization inducer, mast cell stabilizer, choroidal resident immune cell function regulator such as chemical mediator release inhibitor or lactic acid bacteria in 100% by weight of the pharmaceutical composition can be appropriately set within the range of 0.001 to 99.99% by weight.
[0097] The dosage of the pharmaceutical composition disclosed herein is not particularly limited and can be appropriately selected according to the dosage form, the age and weight of the subject of administration, the degree of the desired effect, etc. The dosage of choroidal resident immune cell function regulators such as M2 macrophage polarization inducers, mast cell stabilizers, chemical mediator release inhibitors, or lactic acid bacteria can be, for example, 100 to 1,000,000 nmol per day, preferably 150 to 100,000 nmol, and the frequency of administration can be, for example, 1 to 100 times per month.
[0098] In addition, the composition of the present disclosure may be a food or a supplement. As the form of the food or supplement, for example, liquid, solid, tablet, granular, powder, capsule, paste, gel, etc., such as the above-mentioned solid or liquid preparations, etc., can be arbitrarily selected. Specific examples of food include beverages such as fruit juice drinks, vegetable juices, soft drinks, teas, soups, puddings, yogurts, cake premix products, snacks, biscuits, candies, soft candies, chewing gums, etc., and various general processed foods, such as special-purpose foods, special health foods, nutritional functional foods, functional foods, nutritional supplement foods, health supplement foods, nutritionally fortified foods, nutritionally conditioned foods, etc., such as supplements, oral liquids, etc.
[0099] The food or supplement of the present disclosure may include any functional material (vitamins, minerals, etc.), any excipient, any additive (flavoring agent, sweetener, acidulant, coloring agent, thickener, binder, fortifier, disintegrant, buffer, surfactant, solubilizer, reabsorption promoter, dispersant, stabilizer, gelling agent, emulsifier, antioxidant, surfactant, preservative, moisture-proof agent, pH adjuster, coloring agent, soothing agent, isotonic agent, etc.).
[0100] One aspect of the present disclosure relates to the use of an M2 macrophage polarization inducer, a mast cell stabilizer, a chemical mediator release inhibitor, or other choroidal resident immune cell function regulator or lactic acid bacteria for inhibiting or treating myopia. In addition, another aspect of the present disclosure relates to the use of an M2 macrophage polarization inducer, a mast cell stabilizer, a chemical mediator release inhibitor, or other choroidal resident immune cell function regulator or lactic acid bacteria in the preparation of a drug for inhibiting or treating myopia.
[0101] [Screening method]
[0102] One aspect of the present disclosure relates to a screening method for finding a component that promotes polarization of macrophages into M2 macrophages, which is used to control choroidal thinning as a mechanism of myopia, and a screening method for finding an effective component for preventing and treating myopia.
[0103] In some embodiments, the screening method comprises (i) administering a candidate substance to a model animal, and (ii) measuring the axial length, choroidal thickness and refractive power of the model animal. In some embodiments, the screening method comprises (i) administering a candidate substance to a model animal, and (ii) measuring the expression of choroid-resident immune cell markers such as M2 macrophage markers in samples from the model animal. In some embodiments, the screening method further comprises (iii) measuring the expression of choroid-resident immune cell markers such as M1 macrophage markers.
[0104] In addition, in some embodiments, an in vitro screening method is also included, in which cells such as monocytic cell lines such as RAW264 cells, J774 cells and U937 cells, and choroid-resident immune cells such as mouse peritoneal macrophages and bone marrow-derived macrophages are cultured in a culture medium containing a candidate substance to evaluate the expression of choroid-resident immune cell markers such as M2 macrophage markers.
[0105] In some embodiments, the model animal may be an animal undergoing myopia-inducing treatment.
[0106] In some embodiments, the choroidal resident immune cell markers such as M2 macrophage markers can be CD163, CD206, arginase, IL-10. Choroidal resident immune cell markers such as macrophage markers can be determined by quantitative PCR, flow cytometry, immunostaining, luciferase detection, arginase activity staining, etc.
[0107] Substances identified by this screening method can be used to inhibit or treat myopia.
[0108] Although preferred embodiments of the present invention are shown here, it should be clear to those skilled in the art that such embodiments are provided for exemplary purposes only, and those skilled in the art will be able to make various modifications, changes and substitutions without departing from the present invention. It should be understood that various alternative embodiments of the invention described herein may be used in implementing the present invention. In addition, this application also claims priority to Japanese patent application number 2022-72596, the contents of which, as well as the contents recorded in all publications including patents and patent application documents referenced herein, should be interpreted as being incorporated herein by reference as well as the contents indicated herein.
[0109] Example
[0110] Hereinafter, the present invention will be described in further detail based on experimental examples.
[0111] <Test Example 1 Choroidal thinning and myopia caused by LPS administration>
[0112] To confirm whether polarization into M1 macrophages is associated with choroidal thinning and myopia, the expression of polarization marker genes in the choroid after LPS administration and the measurement of choroidal thickness, axial length, and refractive index were performed.
[0113] Choroidal thickness, axial length, and refractive power were measured in mice administered LPS for two weeks and control mice administered PBS, and their changes were calculated ( Figure 1 A, B). The eyeballs were then removed and the expression of polarization marker genes was measured by quantitative PCR ( Figure 2 ).
[0114] C57BL6J mice were used (n=4 in each group).
[0115] In the LPS administration group, an LPS solution was intraperitoneally injected at a dosage of 10 mg / kg BW every day.
[0116] In the PBS administration group, PBS was administered instead of the LPS solution.
[0117] (Measurement of axial length, choroidal thickness, and refractive power)
[0118] The axial length, choroidal thickness, and diopter of each group of mice were measured. Axial length and choroidal thickness were measured using spectral domain optical coherence tomography (Envisu R4310, manufactured by Leica). Diopter was measured using an infrared photorefractor for mice (Infrared photorefractor for mice made by Professor Schaeffel of the University of Tubingen).
[0119] (Observation of the choroid using an electron microscope)
[0120] The eyes of mice in each group were collected, fixed with 2.5% glutaraldehyde in PBS (Phosphate Buffered Saline) at 4°C overnight, and rinsed with 0.1M sodium cacodylate buffer for 1 hour. Then, after fixing with 1% OsO4 in 0.1M sodium cacodylate buffer for 2 hours, they were dehydrated in graded ethanol solutions. The eyes were then immersed in a 1:2 mixture of propylene oxide and epon-araldite overnight and embedded in 100% resin. The blocks were cut and observed using a transmission electron microscope (JEM1400 plus; JEOL) at an accelerating voltage of 100 kV.
[0121] (Evaluation of Gene Marker Expression)
[0122] As described above, choroid, retina, and sclera samples were collected from mice administered LPS for two weeks and analyzed for the expression of M1 macrophage marker genes and oxidative stress-related genes by quantitative PCR.
[0123] (result)
[0124] Compared with the control group administered with PBS, the LPS administration group showed a decrease in refraction during the one-week and two-week administration period ( Figure 1 B left), axial elongation ( Figure 1 B center), choroidal thinning ( Figure 1 B right).
[0125] In addition, gene expression analysis showed that the expression of M1 marker genes and oxidative stress-related genes was elevated, especially in the choroid ( Figure 2 ).
[0126] As shown by these results, an increase in M1 macrophages in the choroid induces myopia.
[0127] <Test Example 2 Polarization to M2 macrophages and myopia suppressive effect caused by administration of IL-4 and IL-13>
[0128] M1 macrophages are mainly involved in the production of inflammation, while M2 macrophages are involved in the termination and inhibition of inflammation and have an antagonistic effect. Since M1 macrophages have the effect of inducing myopia, it is believed that M2 macrophages have an inhibitory effect on myopia and its development.
[0129] Therefore, we administered IL-4, a cytokine required for polarization into M2 macrophages, to mice, and analyzed the expression of M2 macrophage markers CD163 and CD206 to determine whether polarization into M2 occurred in the choroid ( Figure 3 A, B).
[0130] <Administration of IL-4>
[0131] C57BL6J mice (n = 4 per group) were intraperitoneally administered with 0.1 μg / 100 μl (10 μg / kg BW) of IL-4 solution. Choroidal, retinal, and liver samples were collected at 0 h (before administration) and 4, 24, and 48 h after administration, and the expression of M2 macrophage marker genes was analyzed by Western blotting and real-time PCR ( Figure 3 In addition, choroid and retinal samples were collected at 0 h (before administration) and 4 and 24 h after administration, and the expression of oxidative stress-related genes was analyzed by real-time PCR ( Figure 4 ).
[0132] In addition, IL-4 was administered to mice undergoing myopia induction, and its myopia-suppressing effect was evaluated ( Figure 4 ).
[0133] 0.1 μg / 100 μl (10 μg / kg BW) IL-4 solution was intraperitoneally administered to C57BL6 mice (-30D lens, n=4) undergoing myopia induction for three weeks. C57BL6J mice (0D lens, -30D lens, n=4 per group) undergoing myopia induction were used as a control group. After three weeks, refraction, axial elongation, and choroidal thinning were measured in the same manner as in Test Example 1.
[0134] (result)
[0135] The results showed that the expression of CD163 and CD206, which are M2 markers, in the choroid was increased by the administration of IL-4 ( Figure 3 B, C), confirming the polarization toward M2 macrophages. In addition, gene expression analysis showed that the expression of M2 macrophage marker genes was increased, and the expression of oxidative stress-related genes was inhibited ( Figure 5 ). These results suggest that by administering IL-4, polarization toward M2 macrophages was induced, the expression of oxidative stress-related genes was suppressed, and the development of myopia was inhibited ( Figure 5 ).
[0136] Furthermore, it was demonstrated that the reduction in refractive power was suppressed by administration of IL-4 during myopia induction ( Figure 5 B left), inhibiting axial elongation ( Figure 5 B center), inhibited choroidal thinning ( Figure 5 B right).
[0137] The above results confirmed that the polarization of choroidal macrophages to M2 caused by the administration of IL-4 showed a myopia-suppressing effect.
[0138] <Administration of IL-13>
[0139] Similar to IL-4, IL-13, which is known as a cytokine that polarizes macrophages to M2, was administered during the myopia induction period. Similar to the results with IL-4, it was confirmed using C57BL6J mice that axial elongation, myopia in refraction, and choroidal thinning caused by wearing minus lenses were suppressed, and polarization of macrophages to M2 was induced ( Figure 6 ).
[0140] It should be noted that the changes in blood flow and the number of macrophages were measured as follows.
[0141] Blood flow changes were measured using a wavelength scanning optical coherence tomography scanner (OCT S-1, Canon).
[0142] After choroid digestion, the cells were stained with F4 / 80 and CD11b antibodies, and the number of macrophages was measured using a flow cytometer (CytoFLEX S, Beckman Courter). The number of M2 macrophages was measured in the same manner as the macrophage number measurement, except that the staining process with CD206 antibody was added.
[0143] As shown in the results of Test Examples 1 and 2, it was confirmed that myopia can be induced or suppressed by controlling the state of choroidal macrophages in particular. From the viewpoint of suppressing the progression of myopia and treating it, promoting polarization to M2 macrophages is particularly effective in achieving this goal.
[0144] <Test Example 3: Inhibition of myopia by instillation of mast cell stabilizer into the eye>
[0145] In order to verify the inhibitory effect of mast cell stabilizer eye drops on the development of myopia, a lens-induced myopia model was used, in which myopia was induced by having mice wear minus lenses. During the myopia induction period, cromolyn solution (4% solution) or pyromirolast potassium (0.1% solution) was administered eye drops once a day.
[0146] According to the above test method, the axial length, refractive power and choroidal thickness of mice and control mice that were induced with myopia for three weeks and given eye drops of cromolyn solution or pemirolast potassium solution were measured, and the changes were calculated ( Figure 7 A, B, C).
[0147] The results showed that the axial length of the negative lens wearing eyes in the control group administered with PBS was longer than that of the control eyes ( Figure 7 A) Refractive myopia ( Figure 7 B) and choroidal thinning ( Figure 7 C) On the other hand, the above-mentioned changes observed in the PBS-administered group were not observed in the groups administered with eye drops of cromolyn solution or pemirolast potassium solution.
[0148] As shown by these results, it was confirmed that the eye drop administration of the mast cell stabilizer inhibited the progression of myopia.
[0149] <Test Example 4 Comparison of myopia suppressing effects of ocular instillation of mast cell stabilizer and ocular instillation of histamine receptor blocker>
[0150] Anti-allergic drugs are roughly divided into two categories: mast cell stabilizers that inhibit mast cell degranulation, and histamine receptor blockers that inhibit the action of histamine secreted by mast cell degranulation. In order to clarify whether the inhibitory effect of mast cell stabilizer eye drops on myopia in Experimental Example 3 is the effect of anti-allergic drugs or due to the inhibition of mast cell degranulation, mice with LIM-induced myopia were given eye drops of pemirolast potassium (0.1% solution) as a mast cell stabilizer, and levocabastine solution (0.025% solution) as a histamine receptor blocker, and their myopia inhibitory effects were compared. The results showed that Figure 8 Shown in.
[0151] like Figure 8 As shown, the results showed that, similar to Test Example 3, the axial lengthening, refractive myopia, and choroidal thinning that occurred in the control group did not occur in the group administered with pemirolast potassium. On the other hand, in the group administered with levocabastine, similar to the control group, axial lengthening, refractive myopia, and choroidal thinning occurred.
[0152] The above results confirm the myopia-suppressing effect of mast cell stabilizers among anti-allergic drugs.
[0153] <Test Example 5: Inhibition of Myopia Progression by Administration of Lactobacillus paracasei>
[0154] Since the induction of M2 macrophages can inhibit the development of myopia, Lactobacillus paracasei contained in Yakult (Yakult Co., Ltd.) was cultured and proliferated as lactic acid bacteria and administered to myopia model mice. The axial length, refractive power and choroidal thickness were measured in the same manner as in Test Examples 3 to 4, and the changes were calculated ( Fig. 9 The results showed that the application of lactic acid bacteria inhibited the progression of myopia ( Fig. 9 ).
Claims
1. A method for inhibiting, improving or treating myopia, comprising: A therapeutically effective amount of a choroid-resident immune cell function modulator or lactic acid bacteria is administered to a subject in need of treatment.
2. The method according to claim 1, wherein: The modulator of choroid-resident immune cell function is an inducer of M2 macrophage polarization, a mast cell stabilizer, or an inhibitor of chemical mediator release.
3. The method according to claim 2, wherein: The M2 macrophage polarization inducer is selected from the group consisting of proteins, peptides, nucleic acids, low molecular weight compounds, and high molecular weight compounds.
4. The method according to claim 2, wherein: The M2 macrophage polarization inducer is selected from the group consisting of IL-4, IL-10, IL-13, TLR2, 4, 7, 9 and their ligands, bisantrene dihydrochloride, triptolide, lovastatin, QS11, regorafenib, sorafenib, ixazomib, GW-843682X, KW 2449, axitinib, JTE 013, purmorphamine, arcyriaflavin A, dasatinib, NVP-LDE225, 1-naphthyl PP1, MGCD-265, and bosutinib.
5. The method according to claim 2, wherein: The mast cell stabilizer or chemical mediator release inhibitor is cromolyn, or pemirolast or a salt thereof.
6. The method according to claim 1, wherein: Lactic acid bacteria are of the genus Lactobacillus.
7. The method according to claim 1, wherein: The lactic acid bacteria is Lactobacillus paracasei.
8. The method according to claim 1, wherein: The choroidal resident immune cell function modulator or lactic acid bacteria is contained in a pharmaceutical composition, a supplement or a food.
9. The method according to claim 1, wherein: Inhibits diopter loss, axial elongation, and / or choroidal thinning.
10. A composition for inhibiting or treating myopia, wherein: Contains a therapeutically effective amount of a choroid-resident immune cell function regulator or lactic acid bacteria.
11. A supplement for inhibiting or improving myopia, wherein: Contains an effective amount of a choroid-resident immune cell function regulator or lactic acid bacteria.
12. A food for inhibiting or improving myopia, wherein: Contains an effective amount of a choroid-resident immune cell function regulator or lactic acid bacteria.
13. Use of a choroidal resident immune cell function regulator or lactic acid bacteria in the manufacture of a drug for inhibiting or treating myopia.
14. Use of a choroidal resident immune cell function regulator or lactic acid bacteria for inhibiting or treating myopia.
Citation Information
Patent Citations
Fuel supply device
JP2022072596A
